Atea Pharmaceuticals, Inc.
bemnifosbuvir/ruzasvir
Hepatitis C virus (HCV)
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for bemnifosbuvir/ruzasvir in Hepatitis C virus (HCV) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“C-FORWARD topline results are anticipated around year-end 2026.”